Ciclo celular/Ponto de verificação
Os inibidores do ciclo celular/ponto de verificação são compostos que interrompem a progressão normal do ciclo celular, particularmente em pontos de verificação regulatórios chave. Esses inibidores são cruciais para estudar a divisão celular, entender a proliferação de células cancerígenas e desenvolver terapias anticâncer. Ao direcionar fases específicas do ciclo celular, esses inibidores podem induzir a parada do ciclo celular, levando à apoptose ou senescência em células de divisão rápida. Na CymitQuimica, oferecemos uma ampla gama de inibidores de alta qualidade do ciclo celular/ponto de verificação para apoiar sua pesquisa em biologia do câncer, biologia celular e desenvolvimento de medicamentos.
Subcategorias de "Ciclo celular/Ponto de verificação"
- Aurora Quinase(94 produtos)
- CDK(500 produtos)
- Ciclo celular/Parada(4 produtos)
- Chk(42 produtos)
- DYRK(48 produtos)
- Dinamina(23 produtos)
- Ferroptose(215 produtos)
- HSP(169 produtos)
- Integrinas(224 produtos)
- Cinesina(66 produtos)
- LIM Quinase(19 produtos)
- Microtúbulo associado(261 produtos)
- PKC(102 produtos)
- PLK(28 produtos)
- ROCK(70 produtos)
- Rho(2 produtos)
- Wee1(15 produtos)
- c-Myc(69 produtos)
Exibir 10 mais subcategorias
Foram encontrados 3477 produtos de "Ciclo celular/Ponto de verificação"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PKMYT1-IN-7
CAS:<p>PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.</p>Fórmula:C17H18FN5O3Cor e Forma:SolidPeso molecular:359.355PolQi1
CAS:<p>PolQi1 is a highly efficient and selective Polϴ (DNA polymerase theta) inhibitor with an IC50 of 2 nM, showing potential for cancer therapy.</p>Fórmula:C18H14ClF5N4O2Pureza:98.97%Cor e Forma:SolidPeso molecular:448.77NusB-IN-1
<p>NusB-IN-1 (22r) is an oral bacterial rRNA inhibitor, effective against MRSA and VRSA.</p>Fórmula:C21H16N2O3Cor e Forma:SolidPeso molecular:344.36ROCK-IN-11
CAS:<p>ROCK-IN-11 (example 94) is an effective inhibitor of ROCK1 and ROCK2, with an IC50 of ≤ 5 μM, and plays a significant role in cancer research.</p>Fórmula:C22H20N4O4SCor e Forma:SolidPeso molecular:436.484WEE1-IN-11
CAS:<p>WEE1-IN-11 (Compound 13) serves as a potent CDK2 inhibitor with an IC50 of 2.0 nM. It exhibits inhibitory effects on several cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with respective IC50 values of 93.9, 34.5, 86.7, 23.1, and 85 nM.</p>Fórmula:C26H29FN8OS2Cor e Forma:SolidPeso molecular:552.69PPA-037
CAS:<p>PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.</p>Fórmula:C25H27N7Cor e Forma:SolidPeso molecular:425.53WEE1 degrader 1
<p>WEE1degrader 1 (Compound 10) functions as a Wee1 degrader, exhibiting a DC50 value of 1.5 nM against Wee1. This compound also possesses anticancer properties that inhibit cell proliferation.</p>Fórmula:C30H31N5O3Cor e Forma:SolidPeso molecular:509.6CDK2-IN-18
CAS:<p>CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].</p>Fórmula:C21H23N7O2SCor e Forma:SolidPeso molecular:437.52Haspin-IN-1
<p>Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.</p>Fórmula:C12H8N4O2SCor e Forma:SolidPeso molecular:272.28Uridine 3',5'-diphosphate
CAS:<p>Uridine 3′,5′-diphosphate (3′,5′-UDP; Compound pUp) serves as a competitive RNase inhibitor [1].</p>Fórmula:C9H14N2O12P2Cor e Forma:SolidPeso molecular:404.16Dyrk1A-IN-4
CAS:<p>Dyrk1A-IN-4, compound 48, is an oral DYRK1A/DYRK2 inhibitor with IC50s: 2 nM (DYRK1A), 6 nM (DYRK2), anticancer properties.</p>Fórmula:C14H13F3N6Cor e Forma:SolidPeso molecular:322.29DHX9-IN-9
CAS:<p>DHX9-IN-9 (509) acts as an inhibitor of the RNA helicase DHX9, demonstrating an EC50 of 0.0177 μM in DHX9 cellular target engagement, primarily utilized in cancer research [1].</p>Fórmula:C21H21ClFN5O3S2Cor e Forma:SolidPeso molecular:510Plevitrexed
CAS:<p>Plevitrexed, an oral TS inhibitor (Ki: 0.44 nM), targets α-folate receptor & reduced folate carrier, treats gastric cancer.</p>Fórmula:C26H25FN8O4Pureza:98%Cor e Forma:SolidPeso molecular:532.532′-O-MOE-CMP
CAS:<p>2′-O-MOE-CMP is a nucleotide analogue utilized in the synthesis of oligonucleotides.</p>Fórmula:C12H20N3O9PCor e Forma:SolidPeso molecular:381.28RAD51-IN-8
<p>RAD51-IN-8 inhibits RAD51-BRCA2 interaction and H4A4 with EC50 of 19 μM; a micromolar PPI inhibitor.</p>Fórmula:C16H14Cl2FN3O2Cor e Forma:SolidPeso molecular:370.21CIB-L43
CAS:<p>CIB-L43 is a oral TRBP inhibitor, inhibit miR-21, increase PTEN and Smad7, and block the AKT and TGF-β，inhibit proliferation and migration.</p>Fórmula:C15H16N2O3SPureza:99.64%Cor e Forma:SolidPeso molecular:304.36Cdc7-IN-18
CAS:<p>Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).</p>Fórmula:C19H21N5OSCor e Forma:SolidPeso molecular:367.47Polθ-IN-8
CAS:<p>Polθ-IN-8 (example 77) is a DNA polymerase θ (Polθ) inhibitor with an IC50 for Polθ ATPase activity of less than 100 nM. Polθ-IN-8 is useful for researching diseases related to Polθ activity, such as cancer.</p>Fórmula:C22H22ClN7O3SCor e Forma:SolidPeso molecular:499.97Cdc7-IN-19
CAS:<p>Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].</p>Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.40CDK8-IN-14
CAS:<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>Fórmula:C18H13N3O2Cor e Forma:SolidPeso molecular:303.31
